C12N 2710/16241
Use of virus, viral particle or viral elements as a vector
C12N2710/16241 (Use of virus, viral particle or viral elements as a vector) appears on 40 US grants and 39 published applications in this corpus.
Search patents in C12N- Granted patents
- 40
- Published applications
- 39
- Assignees
- 30
- Inventors
- 100
- Latest grant
- 27 Oct 2020
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1987 | 1 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 1 | 0 |
| 1991 | 1 | 0 |
| 1992 | 1 | 0 |
| 1993 | 1 | 0 |
| 1994 | 1 | 0 |
| 1995 | 0 | 0 |
| 1996 | 1 | 0 |
| 1997 | 4 | 0 |
| 1998 | 2 | 0 |
| 1999 | 1 | 0 |
| 2000 | 1 | 0 |
| 2001 | 3 | 0 |
| 2002 | 1 | 1 |
| 2003 | 1 | 0 |
| 2004 | 0 | 1 |
| 2005 | 0 | 9 |
| 2006 | 0 | 4 |
| 2007 | 0 | 0 |
| 2008 | 1 | 2 |
| 2009 | 2 | 4 |
| 2010 | 6 | 1 |
| 2011 | 2 | 2 |
| 2012 | 0 | 2 |
| 2013 | 1 | 3 |
| 2014 | 1 | 2 |
| 2015 | 2 | 1 |
| 2016 | 2 | 3 |
| 2017 | 0 | 0 |
| 2018 | 1 | 0 |
| 2019 | 1 | 2 |
| 2020 | 1 | 0 |
| 2021 | 0 | 0 |
| 2022 | 0 | 0 |
| 2023 | 0 | 0 |
| 2024 | 0 | 1 |
| 2025 | 0 | 0 |
| 2026 | 0 | 1 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C12N 2710/16243Viral genome or elements thereof as genetic vectorIndexing code29
- C12N 2710/16244Chimeric viral vector comprising heterologous viral elements for production of another viralIndexing code10
- C12N 2710/16242Virus or viral particle as vehicleIndexing code1
- C12N 2710/16245Special targeting system for viral vectorsIndexing code0
Recent patents
- Methods for inducing migration by dendritic cells and an immune response27 Oct 2020US 10,815,458 B2University of Miami
- Method for augmenting vision in persons suffering from photoreceptor cell degeneration16 Apr 2019US 10,259,857 B2The General Hospital Corporation
- Methods for inducing migration by dendritic cells and an immune response23 Oct 2018US 10,106,774 B2University of Miami
- Second generation virus-like particles (VLP) from Epstein-Barr viruses for vaccination purposes13 Dec 2016US 9,517,261 B2Deutsches Krebsforschungszentrum
- Method for augmenting vision in persons suffering from photoreceptor cell degeneration6 Sep 2016US 9,434,781 B2The General Hospital Corporation
- Monoclonal antibody isolation26 Feb 2026US 2026/0055165 A1Imperial College Innovations Limited
- Improved reprogramming, maintenance and preservation for induced pluripotent stem cells1 Feb 2024US 2024/0034999 A1Fate Therapeutics, Inc.
- Method for augmenting vision in persons suffering from photoreceptor cell degeneration29 Aug 2019US 2019/0263883 A1The General Hospital Corporation
- Methods for Inducing Migration by Dendritic Cells and An Immune Response17 Jan 2019US 2019/0017024 A1University of Miami
- Multi-epitopic vaccine4 Feb 2016US 2016/0031946 A1Hopitaux Universitaires De Geneve
Most cited
By later US patents
- Immunizing compositions comprising nucleic acids encoding the HIV-1 matrix protein myristate binding site1,449US 7,718,180 B22010
- Production of recombinant adeno-associated virus vectors369US 5,173,414 AApplied Immune Sciences, Inc. · 1992
- Mammalian interleukin-4156US 5,017,691 ASchering Corporation · 1991
- Recombinant adeno-associated virus vector packaging cells and methods for use86US 5,691,176 AApplied Immune Sciences, Inc. · 1997
- Production of recombinant adeno-associated virus vectors75US 5,354,678 AApplied Immune Sciences, Inc. · 1994